<DOC>
	<DOCNO>NCT00974987</DOCNO>
	<brief_summary>RATIONALE : Boron neutron capture therapy radiation therapy use high-energy x-ray type radiation kill tumor cell . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving boron neutron capture therapy follow radiation therapy temozolomide may kill tumor cell . PURPOSE : This phase II trial study side effect give boron neutron capture therapy together radiation therapy temozolomide treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Boron Neutron Capture Therapy , Radiation Therapy , Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate overall survival patient newly diagnose glioblastoma multiforme treat boron neutron capture therapy , radiotherapy , concurrent adjuvant temozolomide . - Evaluate tumor response patient treat regimen . - Evaluate adverse effect regimen patient . OUTLINE : This multicenter study . Patients undergo boron neutron capture therapy follow radiotherapy concurrent adjuvant oral temozolomide .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Boron</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme Newly diagnose disease Tumor locate supratentorial hemisphere Deepest part tumor &lt; 6 cm scalp Bottom tumor &gt; 6 cm scalp allow provide air instillation tumorremoved cavity possible No cerebrospinal fluid dissemination PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy &gt; 3 month Leukocyte count ≥ 3,000/μL Platelet count ≥ 10.0 × 10^4/μL Hemoglobin ≥ 8.0 g/dL Serum creatinine ≤ 1.5 mg/dL ALT AST ≤ 100 IU/L No phenylketonuria Not pregnant nursing No NYHA class IIIIV heart failure No patient whose participation present study consider inappropriate Principal Investigator Clinical Investigator PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>